Jerry Ji will take up the position as the Chief Executive Officer of Manulife in Hong Kong and Macau on July 1st.

2026-05-22 11:01

Zhitongcaijing
Manulife stated that this appointment reflects Manulife's longstanding emphasis on talent development, continuity of strategy, and commitment to driving long-term growth in Hong Kong and Macau businesses. Through comprehensive succession planning, it further implements its strategy optimization.
On May 22nd, AIA (00945) announced a strategic personnel adjustment in its senior management team for Hong Kong and Macau, appointing Wilton Kee as the Chief Executive for AIA Hong Kong and Macau, pending regulatory approval. Wilton Kee will take over from Patrick Graham as the Chief Executive for AIA Hong Kong and Macau starting from July 1st.
AIA stated that this appointment reflects their commitment to talent development, strategic continuity, and driving long-term growth in Hong Kong and Macau operations. Through comprehensive succession planning, they aim to further enhance their optimization of corporate strategy.
Steve Finch, AIA's President and CEO for Asia, commented that Wilton Kee's appointment demonstrates the group's continued strong execution, diversified business model, and long-term commitment to clients in Hong Kong and Macau, which are among their largest markets in Asia.
Steve Finch mentioned that Wilton Kee brings deep and diverse professional experience as well as a forward-looking strategic vision, which will help drive the company's continued growth. During his recent role as Deputy Chief Executive and CFO for Hong Kong and Macau, he strengthened AIA's market position, promoted business integration, enhanced operational governance, and focused on key projects in strategy and operations. This appointment reflects confidence in Wilton Kee's ability to lead the company in implementing long-term growth strategies as the Chief Executive for Hong Kong and Macau.
Wilton Kee joined AIA in 2013 and has held various senior management positions in Hong Kong and Macau, covering pricing, product, health, and finance. He previously served as Chief Product Officer, later assuming the role of Health Director. In 2022, he was appointed as Chief Financial Officer, and in March 2026, he also took on the role of Deputy Chief Executive, making significant contributions to the company's strategic development and market leadership in both regions.